AI
Wednesday, July 25, 2012 10:31:05 AM
They updated the Corp. Fact Sheet on July 18th
http://www.peregrineinc.com/images/stories/pdfs/fact_sheet_12-07-18.pdf
A couple of things I noticed:
Avid: "New product launches expected by 3rd party clients" (was discussed at JMP and in 7-16-12 CC)
"Validating Phase II Bavituximab Data in 2nd Line NSCLC
Top-line results from the randomized, double-blinded, placebo-controlled Phase II trial evaluating bavituximab with docetaxel vs. docetaxel with placebo (control arm) in 2nd-Line NSCLC patients showed a doubling of overall response rates (ORR), the primary endpoint, and an improvement in progression-free survival (PFS), the secondary endpoint, in patients treated in the bavituximab-containing arms when compared to the control arm. Median overall survival (OS), in the control arm has already been determined at less than 6 months, while as of July 2012 the median OS had not been reached in either bavituximab-containing arm. Median OS data from the trial is expected in the 2nd Half of 2012.”
Updated Bavi milestones chart…
*I think it very interesting that the prev. chart (from the 6-1-12 Factsheet) showed MOS from Front-Line NSCLC trial due Q3-Q4’12 – now they’re showing Q4’12 (JMP 7-12-12 also showed Q3-Q4). Recall, the front-line trial comp. enrollment 9-8-11.
= = = = = = = = = = = = = = = = = = = =
*Note “Q3-Q4’12” for Front-Line NSCLC MOS in prev. 6-1-12 Factsheet, and also in S.King’s 7-12-12 JMP/NYC Talk – 7-18-12 Factsheet now shows Q4’12:
http://www.peregrineinc.com/images/stories/pdfs/fact_sheet_12-07-18.pdf
A couple of things I noticed:
Avid: "New product launches expected by 3rd party clients" (was discussed at JMP and in 7-16-12 CC)
"Validating Phase II Bavituximab Data in 2nd Line NSCLC
Top-line results from the randomized, double-blinded, placebo-controlled Phase II trial evaluating bavituximab with docetaxel vs. docetaxel with placebo (control arm) in 2nd-Line NSCLC patients showed a doubling of overall response rates (ORR), the primary endpoint, and an improvement in progression-free survival (PFS), the secondary endpoint, in patients treated in the bavituximab-containing arms when compared to the control arm. Median overall survival (OS), in the control arm has already been determined at less than 6 months, while as of July 2012 the median OS had not been reached in either bavituximab-containing arm. Median OS data from the trial is expected in the 2nd Half of 2012.”
Updated Bavi milestones chart…
*I think it very interesting that the prev. chart (from the 6-1-12 Factsheet) showed MOS from Front-Line NSCLC trial due Q3-Q4’12 – now they’re showing Q4’12 (JMP 7-12-12 also showed Q3-Q4). Recall, the front-line trial comp. enrollment 9-8-11.
= = = = = = = = = = = = = = = = = = = =
*Note “Q3-Q4’12” for Front-Line NSCLC MOS in prev. 6-1-12 Factsheet, and also in S.King’s 7-12-12 JMP/NYC Talk – 7-18-12 Factsheet now shows Q4’12:
